Migraine aura cannot be reliably stopped once it has started, but early treatment during the aura phase can prevent or reduce the headache that follows, and daily preventive therapies can dramatically cut how often auras occur. The underlying event, a slow wave of electrical disruption rolling across the brain’s surface, unfolds over minutes and is largely self-limiting. What you can control is how aggressively you treat the attack at its earliest moment and whether you use preventive strategies to make future auras less frequent. The options span from simple over-the-counter painkillers taken during the visual shimmer to prescription medications and neuromodulation devices that reshape the brain’s tendency to fire these events in the first place.
What Is Actually Happening During an Aura
The visual distortions, tingling, or speech difficulties you experience during a migraine aura trace back to a phenomenon called cortical spreading depolarization. A wave of intense nerve-cell activation sweeps across the brain’s cortex at a pace of roughly 3 to 4 millimeters per minute, followed by a period of suppressed activity. Functional MRI studies have directly observed this wave in people experiencing visual aura, watching it move slowly across the visual cortex in a pattern that matched what the person was seeing.
1PubMed. Mechanisms of migraine aura revealed by functional MRI in human visual cortexThis wave is not just responsible for the aura symptoms themselves. Researchers now believe cortical spreading depolarization also triggers the headache that typically follows, activating pain pathways in the brain’s covering membranes.
2PubMed. Rethinking migraine with aura: Why cortical spreading depolarization (depression), not aura, causes headachesThe initiation of this wave depends on specific types of calcium and glutamate receptors reaching a threshold of activation, which helps explain why drugs that stabilize nerve-cell excitability can reduce aura frequency.
3PubMed Central. Mechanisms of initiation of cortical spreading depressionOne detail that surprises many people: the headache does not always wait politely for the aura to finish. A systematic review cataloging over 160 recorded auras found that in about a quarter of cases the headache began while the aura was still happening, and in about 9% it actually started before the aura did. Only about a third of auras were followed by a clean gap before the headache arrived.
4PubMed Central. What does a migraine aura look like?—A systematic reviewTreating During the Aura to Head Off the Headache
The single most actionable thing you can do when an aura begins is take medication immediately, before the headache phase arrives. Guidelines recommend starting a nonsteroidal anti-inflammatory drug like ibuprofen or aspirin as soon as the aura starts. The goal is not to treat the aura itself, which will generally resolve on its own, but to block or reduce the headache that follows.
5PubMed. Migraine with auraIf NSAIDs or aspirin consistently fail, triptans are the next step. French neurology guidelines recommend using a triptan once the headache begins rather than during the aura, partly because older labeling cautioned against triptan use during the aura phase. But the clinical picture is more nuanced than that. A study tracking migraine attacks in individual patients found that sumatriptan given during the aura phase prevented the headache from developing in about 9 out of 10 attacks. By contrast, when the same patients treated attacks within an hour of headache onset, only about 8 in 10 became pain-free, and treatment given four hours into the headache helped only about 1 in 5.
6PubMed Central. Revisiting the efficacy of sumatriptan therapy during the aura phase of migraineThe difference comes down to a process called central sensitization. Early in an attack, pain signals are still confined to peripheral nerves. As minutes and hours pass, the brain’s central pain pathways become sensitized, and skin tenderness called allodynia develops. In that same study, allodynia was present in only about 5% of attacks treated during the aura, compared to roughly three-quarters of attacks treated four hours late. Once central sensitization sets in, triptans become far less effective. The practical takeaway: timing matters enormously, and the aura itself is your earliest possible warning signal.
6PubMed Central. Revisiting the efficacy of sumatriptan therapy during the aura phase of migraineLamotrigine for Preventing Aura
Most standard migraine preventives, like beta-blockers or topiramate, work primarily on headache frequency. If your main burden is the aura itself, the evidence points toward lamotrigine as the most targeted option. Lamotrigine is an anticonvulsant that stabilizes nerve-cell membranes, and it appears to specifically suppress the cortical spreading depolarization that generates aura symptoms.
In a three-year prospective study of 59 patients with migraine with aura, lamotrigine cut the average monthly aura frequency from about 1.5 to 0.4 and shortened the average aura duration from 27 minutes to 8 minutes. More than three-quarters of patients who saw fewer auras also experienced fewer migraine headaches overall.
7PubMed Central. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with auraAn earlier open study found a similar pattern: about two-thirds of patients responded, and among responders the mean monthly aura count dropped from 4.2 to 0.7. When the drug was stopped, auras returned within a couple of months in most patients and ceased again when lamotrigine was restarted.
8PubMed. Preventing disturbing migraine aura with lamotrigine: an open studyA retrospective comparison of lamotrigine against topiramate found that lamotrigine outperformed topiramate specifically on aura measures. About half of lamotrigine-treated patients reported complete disappearance of their auras, compared to about a third on topiramate. Lamotrigine also shortened individual aura episodes by about 15 minutes per attack, an effect topiramate did not meaningfully achieve.
9PubMed Central. May lamotrigine be an alternative to topiramate in the prevention of migraine with aura? Results of a retrospective studyLamotrigine does have a notable limitation: it doesn’t reduce headache frequency on its own nearly as well as it reduces aura frequency. If you get frequent migraine headaches both with and without aura, you may need a separate preventive for the headaches. The drug also requires a slow dose escalation over several weeks to avoid a potentially serious skin reaction, so it’s not something you can start and expect immediate results from.
Anti-CGRP Antibodies and Their Effect on Aura
The newer class of migraine preventives, monoclonal antibodies targeting the CGRP pathway, were developed primarily to reduce migraine days. Whether they also reduce aura was initially unclear, because many clinical trials didn’t specifically track aura as a separate outcome. That evidence is now starting to accumulate.
A study using erenumab (one of the anti-CGRP antibodies) specifically tracked aura days as an endpoint. Participants started with an average of 8 monthly aura days. After 24 weeks of treatment, aura days dropped by about 5 per month. Even after stopping the drug, the improvement partially persisted, with aura days still about 3 fewer than baseline during a 12-week follow-up period. Bigger aura reductions were linked to having more aura days at the start and to experiencing larger drops in overall migraine days.
10PubMed Central. Effects of erenumab on migraine aura frequency: a REFORM studyCase reports have also documented complete aura disappearance in individual patients taking galcanezumab or erenumab, along with reduced aura duration and intensity in others.
11PubMed Central. Could the New Anti-CGRP Monoclonal Antibodies Be Effective in Migraine Aura? Case Reports and Literature ReviewThe evidence here is still thinner than for lamotrigine when it comes to aura specifically, but these drugs have the advantage of also strongly reducing headache frequency, making them a practical choice if you deal with both aura and frequent headache days.
Neuromodulation Devices
If you prefer a drug-free approach, or if medications haven’t worked well enough, neuromodulation devices offer an alternative route. Two main technologies have evidence behind them for migraine with aura.
Single-pulse transcranial magnetic stimulation, or sTMS, delivers a brief magnetic pulse to the back of the head. The idea is to interrupt the spreading wave of cortical depolarization before it can propagate. An overview of systematic reviews found that TMS roughly doubled the odds of acute relief compared to sham stimulation in episodic migraine patients.
12PubMed Central. Transcranial Magnetic Stimulation as a Therapy for Migraine: An Overview of Systematic ReviewsApplied to the occipital cortex, sTMS is considered effective for the acute treatment of migraine with aura specifically.
13PubMed Central. Neuromodulation in Chronic Migraine: Evidence and Recommendations from the GRADE FrameworkThe devices are handheld, FDA-cleared, and available by prescription. You hold the device against your head when the aura starts and deliver one or more pulses. Some patients use them preventively as well, with regular daily sessions.
Vagus nerve stimulation is the other main option. Noninvasive versions stimulate the vagus nerve through the skin of the neck or ear. A meta-analysis of randomized trials found that cervical vagus nerve stimulation improved the proportion of patients reaching a 50% or greater reduction in attacks, though it didn’t significantly cut the raw number of migraine days. Auricular stimulation, which targets the vagus nerve at the ear, did significantly reduce migraine days and headache intensity in the same analysis.
14PubMed Central. Noninvasive vagus nerve stimulation for migraine: a systematic review and meta-analysis of randomized controlled trialsA separate trial confirmed that vagus nerve stimulation improved quality of life and reduced pain intensity and frequency over four weeks of active use in chronic migraine patients.
15PubMed Central. Effects of vagal nerve stimulation on pain frequency and intensity in chronic migraine in adults: A randomized controlled trialBoth device types have the advantage of minimal side effects compared to daily medications. The tradeoff is cost, since insurance coverage varies, and a learning curve in using them consistently.
Magnesium and Lifestyle Approaches
Magnesium supplementation occupies an interesting middle ground between lifestyle measures and pharmacotherapy. There’s a plausible link between low magnesium and increased susceptibility to the spreading cortical wave that drives aura, and evidence from randomized trials supports magnesium’s role in reducing both acute and chronic migraine.
16PubMed Central. Magnesium and MigraineMagnesium oxide or magnesium citrate in the range of 400 to 600 milligrams daily is commonly recommended by headache specialists, with the main side effect being loose stools at higher doses. It’s inexpensive, widely available, and safe enough to try before committing to prescription preventives.
Broader lifestyle factors also play a documented role in reducing migraine frequency and severity. Regular physical activity, maintaining a healthy weight, consistent sleep patterns, and a balanced diet all contribute to fewer attacks.
17PubMed Central. Lifestyle Modifications for Migraine ManagementTrigger identification is worth doing carefully, though many people overestimate the reliability of their triggers. Common reported triggers include stress, irregular sleep, skipped meals, alcohol, and hormonal fluctuations. A recent assessment of patient awareness found that addressing triggers and developing personalized coping strategies should be part of any migraine management plan, reducing reliance on medication alone.
18PubMed Central. Migraine triggers and lifestyle modifications: an assessment of patients’ awareness and the role of healthcare providers in patient educationCognitive behavioral therapy and biofeedback training are also used as adjuncts. These approaches won’t specifically abolish aura, but they can lower overall migraine frequency by modifying the stress response and autonomic nervous system activity that contribute to attack susceptibility.
How Hormones Influence Aura
Many women with migraine notice that their aura patterns shift around menstruation, pregnancy, or menopause. This isn’t coincidental. Estrogen appears to directly modulate the brain’s susceptibility to the spreading depolarization wave that produces aura, but the relationship is not as simple as “more estrogen equals more aura.”
Animal research suggests that it’s estrogen withdrawal, rather than estrogen itself, that increases susceptibility. In one study using gonadectomized female rats, sustained estrogen treatment followed by abrupt withdrawal significantly increased spreading depolarization frequency compared to controls. The same protocol had no effect in males.
19PubMed Central. Estrogen modulation of cortical spreading depressionA separate experiment found that estrogen treatment increased cortical spreading depolarization susceptibility during the period of high estrogen levels, while withdrawal promptly reduced it, adding complexity to the picture.
20PubMed. Estrogen-dependent effects of 5-hydroxytryptophan on cortical spreading depression in rat: Modelling the serotonin-ovarian hormone interaction in migraine auraProgesterone adds another layer. In animal models, daily progesterone injections elevated spreading depolarization susceptibility, and progesterone withdrawal partially normalized it.
19PubMed Central. Estrogen modulation of cortical spreading depressionFor practical purposes, this means that hormonal transitions, especially the estrogen drop right before menstruation, can be a predictable trigger window for aura. Some women benefit from estrogen supplementation strategies designed to smooth out those dips, though this requires careful discussion with a doctor because estrogen-containing contraceptives carry additional stroke risk in people who have migraine with aura.
When Aura Mimics Something Dangerous
One of the most anxiety-provoking aspects of migraine aura is that its symptoms can look like a stroke or a transient ischemic attack. Visual loss, numbness on one side, difficulty speaking: these overlap significantly between the conditions. If you’ve had migraine with aura before and your current symptoms follow your usual pattern, that’s reassuring but not a guarantee.
There are reliable distinguishing features. Migraine aura typically builds gradually over five minutes or more, with symptoms spreading in a march, from visual to sensory to speech, for instance. Individual symptoms last between 5 and 60 minutes. Visual symptoms tend to include positive phenomena: shimmering lights, zigzag lines, or expanding spots. A stroke or TIA, by contrast, hits all at once, reaching maximum severity in seconds. The symptoms appear simultaneously rather than spreading. And the visual changes tend to be negative, meaning loss of vision, blacking out of part of the visual field, rather than added light patterns.
21PubMed Central. Transient focal neurological symptoms and headache: is it TIA or migraine with aura?That said, if you experience a new type of aura you’ve never had before, aura symptoms that last longer than 60 minutes, or any sudden onset of weakness or vision loss without the gradual build-up, treating it as a potential stroke and seeking emergency care is the right call. The gradual-versus-sudden distinction is the most clinically useful quick test, but it isn’t foolproof.
Less Common Aura Types
Most migraine auras are visual, producing the classic zigzag or shimmering patterns, but some people experience rarer forms that deserve awareness because they’re more frightening and more easily confused with serious neurological events.
Hemiplegic migraine produces temporary weakness or paralysis on one side of the body during the aura phase, which can look exactly like a stroke. It can be familial, passed through a gene mutation, or sporadic. The key feature is that the weakness is fully reversible, but attacks warrant thorough workup to rule out vascular causes, especially when they first appear.
22PubMed Central. Hemiplegic Migraine: An Imitator of Cerebrovascular DiseaseTriptans are generally avoided in hemiplegic migraine because of theoretical concerns about vasoconstriction during a phase of already compromised blood flow, so treatment strategies differ from standard migraine with aura.
Retinal migraine involves temporary vision loss in just one eye, as opposed to the bilateral visual changes of typical aura. A systematic review found that monocular symptoms occur in about 90% of cases, with scotomas in about 84% and transient vision loss approaching 100%. Most episodes resolve within an hour, but rare cases involve permanent visual damage.
23PubMed Central. Differentiating Visual Symptoms in Retinal Migraine and Migraine With Aura: A Systematic Review of Shared Features, Distinctions, and Clinical ImplicationsThe fact that symptoms are monocular is the critical difference: typical migraine aura affects the same part of the visual field in both eyes because the disruption occurs in the visual cortex, not the eye. Retinal migraine is thought to involve vascular changes in the retina itself, and it warrants its own diagnostic workup and preventive approach.
How Brain Imaging Is Sharpening the Picture
Migraine aura has traditionally been diagnosed purely by clinical history, and that remains the primary approach. But functional brain imaging is revealing differences between people who have aura and those who don’t, even between attacks. A recent fMRI study using visual stimulation found that migraine patients with visual aura showed stronger activation in certain brain regions, including the angular gyrus and the cuneus, compared to migraine patients without aura.
24PubMed Central. A preliminary study on brain functional magnetic resonance imaging in migraine patients with visual aura using visual stimulationThese findings aren’t yet useful as a diagnostic test you’d get at your doctor’s office. But they matter for the future of aura treatment, because they suggest that people with aura have persistently different cortical excitability even between attacks, not just a transient event during them. That persistent hyperexcitability is the target that preventive drugs like lamotrigine and devices like TMS aim to dampen. As imaging clarifies which specific circuits are most excitable in a given person, treatments may eventually become more individually tailored, selecting the intervention most likely to work based on that person’s brain activity pattern rather than trial and error.